A
Alphamab Oncology
Sustainability Report and Carbon Intensity Rankings
Is Alphamab Oncology doing their part?
Their DitchCarbon score is 32
Alphamab Oncology has a DitchCarbon Score of 32 out of 100, indicating a lower performance in sustainability measures. This score suggests that the company has a relatively high carbon intensity compared to more sustainable peers. Efforts to reduce emissions and improve sustainability practices are needed to increase their score.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Alphamab Oncology is part of the health and social services industry, which has a low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Unknown
High
Very high
Alphamab Oncology is situated in China, a region with a carbon intensity rating that influences the company’s environmental impact. The sustainability efforts of the company are affected by China’s national strategies and policies on carbon emissions.
Unlock 30+ emissions data points on Alphamab Oncology
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Alphamab Oncology
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
9.56%
...this company is doing 9.56% worse in emissions than the industry average.
Alphamab Oncology, founded in 2015, is a biopharmaceutical company based in China that specializes in the research, development, production, and commercialization of innovative oncology drugs. The company made its debut on the Hong Kong Stock Exchange on December 12, 2019, under the stock code 9966. Operating within the health and social services industry, Alphamab Oncology is dedicated to advancing cancer treatment options.
emission intelligence's platform recommendations for Alphamab Oncology
Alphamab Oncology should undertake a thorough inventory of all Scope 1 emissions sources and pursue energy efficiency improvements throughout its operations, while also shifting to low-carbon or renewable energy sources to potentially reduce emissions by 15%.
Bad news, Alphamab Oncology hasn't committed to SBTi goals yet.
Alphamab Oncology has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining its goals for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.